Economidou-Karaoglou A, Lans M, Taper H, Michaux J L, Roberfroid M
Département des Sciences Pharmaceutiques, Faculté de Médecine, Université de Louvain, Belgium.
Blood. 1989 Dec;74(8):2730-2.
Our previously published clinical results on various malignancies indicated that the variations in serum alkaline DNase activity (SADA) could be a sensitive test for therapeutic monitoring of human malignancies. In the present study, the clinical efficacy of SADA detecting relapse in 32 acute nonlymphoblastic leukemia (ANLL) patients in remission was tested. The observation period ranged from 3 to 17 months. A simple and rapid biochemical technique based on spectrophotometric measurements was used to assay SADA. Of the 32 patients, 17 remained in remission and had less than a 15% variation in SADA levels. They had no clinical symptoms of recurrence at any time. In the remaining 15 patients, after a period of stability, a progressive decrease in SADA, with variations of more than 15%, was observed without any treatment. At that time, no abnormalities of clinical parameters were detected in these patients. A recurrence of disease as evidenced by routine examinations was found relatively late after the first decrease in SADA in all 15 patients (range 1.5 to 5.5 months). These results suggest that periodic measurements of SADA during the posttherapeutic course can be used as a means to assess early detection of an eventual recurrence.
我们之前发表的关于各种恶性肿瘤的临床结果表明，血清碱性脱氧核糖核酸酶活性（SADA）的变化可能是一种用于监测人类恶性肿瘤治疗效果的敏感检测方法。在本研究中，对SADA检测32例急性非淋巴细胞白血病（ANLL）缓解期患者复发情况的临床疗效进行了测试。观察期为3至17个月。采用基于分光光度测量的简单快速生化技术测定SADA。32例患者中，17例仍处于缓解期，SADA水平变化小于15%。他们在任何时候都没有复发的临床症状。其余15例患者在一段稳定期后，未经任何治疗即观察到SADA逐渐下降，变化超过15%。此时，这些患者的临床参数未检测到异常。在所有15例患者中，在SADA首次下降后相对较晚才通过常规检查发现疾病复发（范围为1.5至5.5个月）。这些结果表明，在治疗后过程中定期测量SADA可作为评估最终复发早期检测的一种手段。
